Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 10;44:361–374. doi: 10.1016/j.ebiom.2019.05.008

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 3 — Bestatin suppresses the BLT1-ERK1/2 signaling pathway in CRC patients. (a–c) mRNA levels of BLT1, c-Myc, and Ki-67 in human CRC patient tissues were analyzed by quantitative PCR (qPCR). Relative mRNA levels were normalized against GAPDH. The data are shown as mean values ± S.E. from triplicate experiments and the asterisks (**, ***) indicate a significant (p < .01, p < .001) decrease in tissues from the group treated with bestatin compared with the untreated group. (d) Immunohistochemistry analysis was used to determine the expression of BLT1, p-ERK1/2 (Thr202/Tyr204), c-Myc,and Ki-67 in patients treated with bestatin compared with untreated patients. The asterisks (*, **, ***) indicate a significant (p < .05, p < .01, p < .001, respectively) decrease in protein expression in the bestatin-treated group compared with the untreated group (scale bar, 100 μm). (e) The expression of BLT1, p-MEK (Ser217/221), p-ERK1/2 (Thr202/Tyr204), c-Myc, and Ki-67 was also determined by Western blot.